睿知中国医院研究地图
候选清单

正在招募肺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07336732,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed, unresectable locally advanced (Stage IIIB or IIIC) or metastatic (Stage IV) non-squamous non-small cell lung cancer (NSCLC).

    入选标准第 2 条

  3. ECOG PS ≤1.

    入选标准第 6 条

  4. At least one measurable lesion as defined by RECIST v1.1.

    入选标准第 5 条

  5. History of another active malignancy within the past 5 years (except for specific cured cancers).

    排除标准第 6 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);既往治疗;化验:血常规、肝肾功能;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07336732,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age ≥18 years at the time of ICF signing.
  2. Histologically or cytologically confirmed, unresectable locally advanced (Stage IIIB or IIIC) or metastatic (Stage IV) non-squamous non-small cell lung cancer (NSCLC).
  3. Confirmed EGFR atypical mutation.
  4. No prior systemic therapy for locally advanced or metastatic NSCLC.
  5. At least one measurable lesion as defined by RECIST v1.1.
  6. ECOG PS ≤1.
  7. Life expectancy≥12 weeks.
  8. Adequate organ function confirmed within 7 days prior to the first dose of study treatment
  9. Female participants must use adequate contraceptive measures during study participation and for 90 days after the last dose of study treatment and must not be breastfeeding; female subjects not of childbearing potential must meet at least one of the following criteria at screening: Postmenopausal status; Documentation of irreversible surgical sterilization.
  10. Non-sterilized males: Abstinence or contraception use; No sperm donation.
  11. Willing and able to provide signed ICF and to comply with all requirements and restrictions listed in the ICF and this study protocol.

排除标准:Exclusion Criteria:

  1. Presence of specific genetic alterations for which approved targeted therapies are available.
  2. Recent participation (within 28 days) in another interventional clinical trial.
  3. Major surgery within 28 days prior to study entry or planned during the study period.
  4. Recent use of anti-tumor traditional proprietary medicine or local anti-tumor therapy.
  5. Need for specific concomitant medications (e.g., metformin) that cannot be paused during the study.
  6. History of another active malignancy within the past 5 years (except for specific cured cancers).
  7. Toxicities from prior therapy have not recovered to acceptable levels.
  8. Presence of symptomatic or uncontrolled brain metastases, carcinomatous meningitis, or spinal cord compression.
  9. Symptomatic and uncontrolled third-space fluid accumulations (e.g., pleural effusion, ascites).
  10. Severe cardiovascular/cerebrovascular disease or risk factors (e.g., heart failure, history of myocardial infarction, QT prolongation, uncontrolled hypertension, etc.).
  11. History or presence of interstitial lung disease, or drug/radiation-related pneumonitis.
  12. Active autoimmune or inflammatory diseases.
  13. Active, uncontrolled infection (including HBV, HCV, HIV, syphilis, tuberculosis, etc.).
  14. Gastrointestinal disorders or surgery affecting drug ingestion or absorption.
  15. Active keratitis or ulcerative keratitis.
  16. History of hypersensitivity to the study drug, its analogs, or chemotherapy drugs (pemetrexed/platinum agents).
  17. Recent administration (within 30 days) of a live attenuated vaccine.
  18. Psychiatric disorders or substance abuse potentially affecting compliance.
  19. Any other condition deemed by the investigator as unsuitable for study participation.

引自 ClinicalTrials.gov, NCT07336732, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07336732,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07336732